Name: Japan Daiichi Sankyo Transamin Tablets: Tranexamic Acid (250 mg, 500 mg): 100 tablets. Skin-brightening pills that lighten dark spots, brighten the complexion, and reduce melanin deposition.
SKU: 3225
Price: 620 HKD
Availability: InStock

描述

Antifibrinolytic Agents | Direct Shipping from Overseas (Direct from Japan)

Tranexamic Acid
250 mg tablets / 500 mg tablets
Capsule 250 mg / Powder 501 TP3T
TRANSAMIN Tablets / Capsules / Powder

Revised January 2023 (1st Edition) | Classification 873327/87449 | Antiplasmin Agents

Systemic/Localized Hyperfibrinolysis and Bleeding | Eczema, Urticaria, and Drug Rash | Tonsillopharyngitis | Stomatitis

Admission, etc.

250 mg tablet	YJ 3327002F1142 Approval 21400AMZ00148 Sales began in September 1976 Nichiku Tranexamic Acid Tablets—White Coated Tablets φ10.0 mm / Approx. 3.2 mm thick / Approx. 290 mg Identification 606
500 mg tablet	YJ 3327002F2041 Approval 15300AMZ01211 Sales began in September 1981 Nichiku Tranexamic Acid Tablets: White to pale yellowish-white film-coated tablets 17.8 × 7.2 mm / Approx. 5.0 mm thick / Approx. 574 mg ID 608
250 mg capsule	YJ 3327002M1303 Approved 22000AMX01511 Sales began in October 1965 Nichiku Tranexamic Acid Capsules No. 2: Total length 17.8 mm / Approx. 348 mg Cap: orange, opaque / Body: white, opaque; Contents: white powder; Identification: 605
Loose 50%	YJ 3327002B1027 Approval No. 21400AMZ00141 Sales began in August 1970 Generic Name: Tranexamic Acid Powder; White powder; 500 mg per 1 g
Storage Instructions / Expiration Date	Store at room temperature / 3 years
Manufacturing and Sales Yuan	Daiichi Sankyo Co., Ltd. 3-5-1 Nihonbashi-Honcho, Chuo Ward, Tokyo
Packaging	Tablet 250: 500 tablets in a plastic bottle; PTP blisters of 100 or 500 tablets Tablets 500: PTP 100/500 tablets Capsules: PTP 100/500 capsules Loose: Aluminum-laminated bag, 100g
Shipping method	Direct overseas shipping (Direct shipping from Japan)
Preparation and shipping time	Once payment and prescription eligibility have been verified, orders are typically shipped within 4 to 7 business days.

3. Composition

250 mg tablet

Active Ingredients:1 tablet of Japan Pharmaceutical Bureau Tranexamic Acid 250 mg

Additive:Corn starch, polyvinyl alcohol (partially saponified), low-substituted hydroxypropyl cellulose, magnesium stearate, hydrogenated oil

500 mg tablet

Active Ingredients:1 tablet contains 500 mg of Japanese-made tranexamic acid

Additive:Calcium carboxymethyl cellulose, polyvinyl alcohol (partially saponified), magnesium stearate, hydroxypropyl methylcellulose, polyethylene glycol 6000, talc, titanium dioxide, dimethylpolysiloxane, silicon dioxide, carnauba wax

Capsule 250 mg

Active Ingredients:1 capsule containing 250 mg of Tranexamic Acid (Japan and China)

Additive:Corn starch, magnesium stearate; Capsule: gelatin, sodium lauryl sulfate, Yellow No. 5

Loose 50%

Active Ingredients:1g Japan-China Bureau Tranexamic Acid 500mg

Additive:D-mannitol, polyvinyl alcohol (partially saponified)

C₈H₁₅NO₂　Molecular weight: 157.21. White crystals or crystalline powder; readily soluble in water.

Structural Formula

4.／6. Efficacy and Effects; Dosage and Administration

Bleeding tendencies associated with systemic hyperfibrinolysis (leukemia, aplastic anemia, purpura, etc., as well as intraoperative and postoperative abnormal bleeding)
Abnormal Bleeding Associated with Localized Hyperfibrinolysis (Pulmonary Hemorrhage, Epistaxis, Genital Bleeding, Renal Hemorrhage, Intraoperative and Postoperative Abnormal Bleeding Following Prostate Surgery)
Eczema and related conditions, hives, and erythema, swelling, and itching associated with drug rashes or toxic rashes, etc.
Sore throat, redness, congestion, and swelling associated with tonsillitis and laryngopharyngitis, etc.
Mouth Pain and Mucosal Ulcers Associated with Stomatitis

The usual daily dose of tranexamic acid for adults is 750–2,000 mg, taken orally in 3–4 divided doses. The dose may be adjusted based on age and symptoms.

18. Pharmacodynamics and Pharmacology

Fibrinolysis is involved in processes such as fibrin degradation and increased vascular permeability. This agent inhibits the action of plasmin, thereby exhibiting antihemorrhagic, antiallergic, and anti-inflammatory effects.

It strongly binds to the lysine-binding site (LBS) of plasmin/plasminogen, thereby preventing their binding to fibrin; its effect is even stronger in the presence of antifibrinolytic agents such as α₂-macroglobulin. In cases of mild hyperfibrinolysis, fibrinolysis occurs first; this agent stops bleeding by inhibiting this process. It also inhibits the production of active peptides, such as kallikrein, generated by plasmin (in guinea pigs and rats).

16.／17. Pharmacokinetics and Clinical Outcomes

250 mg tablet (n=5)

Cmax 3.9 μg/mL | Tmax 2–3 hr | t½ 3.1 hr

500 mg tablet (n=5)

Cmax 6.0 μg/mL | Tmax 2–3 hr | t½ 3.3 hr

500 mg capsule (n=5)

Cmax 5.5 μg/mL | Tmax 2–3 hr | t½ 3.3 hr

Single-dose plasma concentration

Approximately 40–701 TP3T is excreted unchanged in the urine within 24 hours. In mouse tissues, concentrations are higher in the liver, kidneys, lungs, and pancreas, and lower in the brain.

Hemostatic efficacy in bleeding-related cases: 73.61 TP3T (2,063/2,802). General trials for skin disorders: 60.51 TP3T; double-blind trials showing “effective” or better: 62.91 TP3T vs. placebo 31.31 TP3T (p < 0.05). General trials for ENT/stomatitis: 70.81 TP3T; double-blind trials showing “effective” or better: 52.41 TP3T vs. 26.21 TP3T (p < 0.05).

2. / 9. / 10. / 11. / 14. / 15. Contraindications, Precautions, Interactions, Side Effects

2. Contraindications:Patients currently receiving thrombin [10.1].

10.1 Contraindications for Concomitant Use:Thrombin—promotes thrombus formation; concomitant use may increase the risk of thrombosis.

10.2 Precautions for Concomitant Use:

Hemocoagulase: When used in high doses in combination with other medications, there is a risk of thrombosis (the fibrin clots formed may persist for a longer period due to this drug’s antifibrinolytic effect, leading to prolonged obstruction).
Batroxobin: May cause thrombosis and embolism (by inhibiting the breakdown of desA fibrin polymers it generates).
Coagulation factor preparations (e.g., eptacog alfa): In areas with strong fibrinolytic activity, such as the oral cavity, the coagulation system may be further activated (dual hemostasis through activation of the coagulation system and inhibition of the fibrinolytic system).

9.1:Patients with existing blood clots (such as cerebral thrombosis, myocardial infarction, or thrombophlebitis) or those at risk of developing blood clots, as well as patients with consumptive coagulopathy (for whom concomitant use of heparin or similar agents is recommended), may experience stabilization of the blood clot. Venous thrombosis is more likely to develop in patients who are bedridden or undergoing compression hemostasis postoperatively; cases of pulmonary embolism have been reported after the patient gets out of bed or the compression is removed. Patients with a history of allergy to any of the components.

9.2:Blood concentrations may increase in patients with renal failure. For patients on hemodialysis, see 11.1.1.

September 5, 6, and 8:Pregnant women should take this medication only when the benefits outweigh the risks. The use of this medication while breastfeeding requires careful consideration. Older adults should take a reduced dose.

11.1.1 Serious Adverse Effects:Seizures (frequency unknown) — May occur in patients undergoing hemodialysis [9.2.2].

11.2:Allergic reactions (0.1–11 TP3T): itching, rash, etc.; Gastrointestinal (0.1–51 TP3T) loss of appetite, nausea, vomiting, diarrhea, heartburn; Other (0.1–1 TP3T) drowsiness.

14. PTP must be removed from the tablet before administration; accidental ingestion may cause the tablet to pierce the esophagus or even cause a perforation. 15. There have been reports of retinal degeneration following long-term administration of high doses to dogs.

22–26. Packaging, Inquiries, Manufacturing, and Sales

24. Daiichi Sankyo Co., Ltd. Product Information Center 3-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo 103-8426 TEL 0120-189-132

26.1 Manufacturer and Distributor: Daiichi Sankyo Co., Ltd., 3-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo

※ This page was translated in full by Hkeemall based on PMDA Package Insert 3327002B1027_2_07; it is not a substitute for a doctor’s prescription or the original Japanese version.

Enter "Transamin" in the PMDA "Package Insert Information" field to search for the original version.

[Disclaimer]

The information regarding medications, treatments, or health management contained in this article is compiled from international authoritative medical journals and official clinical literature, and is intended for general science and educational reference only.
The indications, side effects, and contraindications of related medications may vary depending on national regulations and individual physical conditions. Do not blindly take medication on your own or change your treatment plan.
The author and publishing platform assume no legal liability for any medical delays, adverse reactions, or direct or indirect losses caused by the use of the information in this article. All medical decisions should be discussed with your attending physician before being made.

Additional information

Specifications	Daiichi Sankyo Transamin Tranexamic Acid Tablets 500 mg

1 review for 日本第一三共 Transamin トランサミン錠傳明酸妥塞敏氨甲環酸片250mg 500mg：100錠美白丸美白淡斑提亮肌膚減少黑色素沈積

4.00

Rated 4.00 out of 5 based on 1 customer rating

Average of 1 review

5 0

4 1

3 0

2 0

1 0

Rated 4 out of 5

Yiyan Li – August 28, 2026

After taking it for a while, my skin is noticeably fairer and more even, and the dark spots have faded. The whitening effect of tranexamic acid is truly visible, very satisfied!

Add a review

Japan Daiichi Sankyo Transamin Tablets: Tranexamic Acid (250 mg, 500 mg): 100 tablets. Skin-brightening pills that lighten dark spots, brighten the complexion, and reduce melanin deposition.

描述